Home ›
Trademark Categories ›
Pharmaceuticals ›
2007 ›
EP ›
EPRAMET
Trademark search for:
EPRAMET
No active United States Patent and Trademark Office (USPTO) registrations found, based on publicly available USPTO trademark records.
Trademark records may change over time.
For the most up-to-date trademark status, domain availability,
and social handle checks, run a live search.
Check latest trademark, domains & social handles
Live search · Most up-to-date results
USPTO Filing History
Key events recorded for this trademark application
2007-02-22 — Application filed
2007-02-27 — Application filed
2007-05-18 — Assigned to examiner
2007-05-20 — Suspension letter written
2007-05-20 — Letter of suspension e-mailed
2007-11-20 — Suspension inquiry written
2007-11-20 — Inquiry to suspension e-mailed
2007-11-20 — Notification of inquiry as to suspension e-mailed
2007-12-14 — Teas response to suspension inquiry received
2008-01-27 — Assigned to lie
2008-01-29 — Teas/email correspondence entered
2008-01-29 — Correspondence received in law office
2008-01-31 — Approved for pub - principal register
2008-01-31 — Law office publication review completed
2008-02-13 — Notice of publication
2008-03-04 — Published for opposition
2008-05-20 — Registered-principal register
2011-04-04 — Attorney/dom.rep.revoked and/or appointed
2011-04-04 — Teas revoke/app/change addr of atty/dom rep received
2013-07-08 — Attorney/dom.rep.revoked and/or appointed
2013-07-08 — Teas revoke/app/change addr of atty/dom rep received
2014-12-26 — Cancelled sec. 8 (6-yr)
2014-12-26 — Final status recorded
Owner Information
Novo Nordisk A/S
DK-2880 Bagsvaerd DK
Novo Nordisk A/S
DK-2880 Bagsvaerd DK
Novo Nordisk A/S
DK-2880 Bagsvaerd DK
Correspondent
Claudia A. Smith White & Case LLP 1155 Avenue of the Americas Patent and Trademark Department New York, NY 10036
Filing Details
Filing Date:
2007-02-22
Status Date:
2014-12-26
Disclaimer: This page is informational only and does not constitute legal advice.
Trademark availability depends on jurisdiction, usage, and legal interpretation.